Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors

Background Reduced muscle mass has been associated with increased treatment complications in several tumor types. We evaluated the impact of skeletal muscle index (SMI) on prognosis and immune-related adverse events (IrAEs) in a cohort of recurrent/metastatic (R/M) head and neck squamous cell carcin...

Descripción completa

Detalles Bibliográficos
Autores: Arribas, Lorena, Plana, Maria, Taberna, Miren, Sospedra, Maria, Vilariño, Noelia, Oliva, Marc, Pallarès, Natàlia, González Tampán, Ana Regina, Rio, Luis Miguel del, Mesía Nin, Ricard, Baracos, Vickie
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/179337
Acceso en línea:https://hdl.handle.net/2445/179337
Access Level:acceso abierto
Palabra clave:Pronòstic mèdic
Marcadors bioquímics
Càncer de coll
Càncer de cap
Prognosis
Biochemical markers
Neck cancer
Head cancer
id ES_98d509fc83cf258af2eb5614ffbe74dd
oai_identifier_str oai:diposit.ub.edu:2445/179337
network_acronym_str ES
network_name_str España
repository_id_str
spelling Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint InhibitorsArribas, LorenaPlana, MariaTaberna, MirenSospedra, MariaVilariño, NoeliaOliva, MarcPallarès, NatàliaGonzález Tampán, Ana ReginaRio, Luis Miguel delMesía Nin, RicardBaracos, VickiePronòstic mèdicMarcadors bioquímicsCàncer de collCàncer de capPrognosisBiochemical markersNeck cancerHead cancerBackground Reduced muscle mass has been associated with increased treatment complications in several tumor types. We evaluated the impact of skeletal muscle index (SMI) on prognosis and immune-related adverse events (IrAEs) in a cohort of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoints inhibitors (ICI). Methods A single-institutional, retrospective study was performed including 61 consecutive patients of R/M HNSCC diagnosed between July 2015 and December 2018. SMI was quantified using a CT scan at L3 to evaluate body composition. Median baseline SMI was used to dichotomize patients in low and high SMI. Kaplan-Meier estimations were used to detect overall survival (OS) and progression-free survival (PFS). Toxicity was recorded using Common Terminology Criteria for Adverse Event v4.3. Results Patients were 52 men (85.2%) with mean of age 57.7 years (SD 9.62), mainly oral cavity (n = 21; 34.4%). Low SMI was an independent factor for OS in the univariate (HR, 2.06; 95% CI, 1.14-3.73, p = 0.017) and multivariate Cox analyses (HR, 2.99; 95% CI, 1.29-6.94; p = 0.011). PFS was also reduced in patients with low SMI (PFS HR, 1.84; 95% CI, 1.08-3.12; p = 0.025). IrAEs occurred in 29 (47.5%) patients. There was no association between low SMI and IrAEs at any grade (OR, 0.56; 95% CI, 0.20-1.54; p = 0.261). However, grades 3 to 4 IrAEs were developed in seven patients of whom three had low SMI. Conclusions Low SMI before ICI treatment in R/M HNSCC patients had a negative impact on OS and PFS. Further prospective research is needed to confirm the role of body composition as a predictive biomarker in ICI treatment.Frontiers Media SA2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/179337Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3389/fonc.2021.699668Frontiers in Oncology, 2021, vol. 11, num. 699668https://doi.org/10.3389/fonc.2021.699668cc by (c) Arribas, Lorena et al., 2021http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1793372026-05-27T06:46:51Z
dc.title.none.fl_str_mv Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
title Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
spellingShingle Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
Arribas, Lorena
Pronòstic mèdic
Marcadors bioquímics
Càncer de coll
Càncer de cap
Prognosis
Biochemical markers
Neck cancer
Head cancer
title_short Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
title_full Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
title_fullStr Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
title_full_unstemmed Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
title_sort Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
dc.creator.none.fl_str_mv Arribas, Lorena
Plana, Maria
Taberna, Miren
Sospedra, Maria
Vilariño, Noelia
Oliva, Marc
Pallarès, Natàlia
González Tampán, Ana Regina
Rio, Luis Miguel del
Mesía Nin, Ricard
Baracos, Vickie
author Arribas, Lorena
author_facet Arribas, Lorena
Plana, Maria
Taberna, Miren
Sospedra, Maria
Vilariño, Noelia
Oliva, Marc
Pallarès, Natàlia
González Tampán, Ana Regina
Rio, Luis Miguel del
Mesía Nin, Ricard
Baracos, Vickie
author_role author
author2 Plana, Maria
Taberna, Miren
Sospedra, Maria
Vilariño, Noelia
Oliva, Marc
Pallarès, Natàlia
González Tampán, Ana Regina
Rio, Luis Miguel del
Mesía Nin, Ricard
Baracos, Vickie
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Pronòstic mèdic
Marcadors bioquímics
Càncer de coll
Càncer de cap
Prognosis
Biochemical markers
Neck cancer
Head cancer
topic Pronòstic mèdic
Marcadors bioquímics
Càncer de coll
Càncer de cap
Prognosis
Biochemical markers
Neck cancer
Head cancer
description Background Reduced muscle mass has been associated with increased treatment complications in several tumor types. We evaluated the impact of skeletal muscle index (SMI) on prognosis and immune-related adverse events (IrAEs) in a cohort of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoints inhibitors (ICI). Methods A single-institutional, retrospective study was performed including 61 consecutive patients of R/M HNSCC diagnosed between July 2015 and December 2018. SMI was quantified using a CT scan at L3 to evaluate body composition. Median baseline SMI was used to dichotomize patients in low and high SMI. Kaplan-Meier estimations were used to detect overall survival (OS) and progression-free survival (PFS). Toxicity was recorded using Common Terminology Criteria for Adverse Event v4.3. Results Patients were 52 men (85.2%) with mean of age 57.7 years (SD 9.62), mainly oral cavity (n = 21; 34.4%). Low SMI was an independent factor for OS in the univariate (HR, 2.06; 95% CI, 1.14-3.73, p = 0.017) and multivariate Cox analyses (HR, 2.99; 95% CI, 1.29-6.94; p = 0.011). PFS was also reduced in patients with low SMI (PFS HR, 1.84; 95% CI, 1.08-3.12; p = 0.025). IrAEs occurred in 29 (47.5%) patients. There was no association between low SMI and IrAEs at any grade (OR, 0.56; 95% CI, 0.20-1.54; p = 0.261). However, grades 3 to 4 IrAEs were developed in seven patients of whom three had low SMI. Conclusions Low SMI before ICI treatment in R/M HNSCC patients had a negative impact on OS and PFS. Further prospective research is needed to confirm the role of body composition as a predictive biomarker in ICI treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/179337
url https://hdl.handle.net/2445/179337
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3389/fonc.2021.699668
Frontiers in Oncology, 2021, vol. 11, num. 699668
https://doi.org/10.3389/fonc.2021.699668
dc.rights.none.fl_str_mv cc by (c) Arribas, Lorena et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Arribas, Lorena et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media SA
publisher.none.fl_str_mv Frontiers Media SA
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414224732618752
score 15,301629

Similares en LA Referencia